Bioequivalence and Bioavailability Forum

Dear HS,

Thanks for that valuable inputs

However as per Canadian guideline, they have recommended RMANOVA with Day and Day*Treatment effects to be considered. Here, I am prefereing to do a ONE WAY ANOVA (as I am considering last three pre-dose).

Will this approach fulfill the regulatory requirement, as the study is for Europe territory?

Thanks & Regards,
NIRALI